{"id":501694,"date":"2021-06-08T07:36:58","date_gmt":"2021-06-08T11:36:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-welcomes-dr-kevin-a-damour-as-chief-scientific-officer\/"},"modified":"2021-06-08T07:36:58","modified_gmt":"2021-06-08T11:36:58","slug":"brooklyn-immunotherapeutics-welcomes-dr-kevin-a-damour-as-chief-scientific-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-welcomes-dr-kevin-a-damour-as-chief-scientific-officer\/","title":{"rendered":"Brooklyn ImmunoTherapeutics Welcomes Dr. Kevin A. D\u2019Amour as Chief Scientific Officer"},"content":{"rendered":"
\n

BROOKLYN, N.Y., June 08, 2021 (GLOBE NEWSWIRE) — Brooklyn ImmunoTherapeutics<\/a>, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing\/cell therapy can have in treating patients with cancer, blood disorders, and monogenic disorders, today announced the appointment of Kevin A. D\u2019Amour, Ph.D. as its Chief Scientific Officer.<\/p>\n

Dr. D\u2019Amour joins Brooklyn from ViaCyte, Inc., a private, clinical stage company developing stem cell-based therapy for type 1 and insulin-dependent type 2 diabetes, where he most recently served as Chief Scientific Officer. He holds more than 100 U.S. and international patents and has been widely published in nationally and internationally recognized peer review journals. Dr. D\u2019Amour received his Ph.D. in Biology from the University of California, San Diego and his B.S. in Animal Science from the University of New Hampshire in Durham, New Hampshire.<\/p>\n

\u201cKevin\u2019s significant experience in successful early- to clinical-stage development in the area of cell and gene-modified cell therapy makes him an excellent fit at Brooklyn, as we embark on what we believe will be pioneering work in multiple applications, many of which have no current treatments available,\u201d said Howard J. Federoff, M.D., Ph.D., Brooklyn\u2019s Chief Executive Officer and President. \u201cWe look forward to driving our work forward under Kevin\u2019s leadership and we welcome him to Brooklyn.\u201d<\/p>\n

Brooklyn\u2019s exclusive access to the Factor Bioscience and Novellus technologies for mRNA-based gene-editing and cellular reprogramming, combined with the novel mRNA delivery system, provide a robust technology platform with a myriad of compelling therapeutic approaches. I look forward to helping successfully bring those approaches to the clinic and ultimately to patients,\u201d added Dr. D\u2019Amour.\u00a0<\/p>\n

\n About Brooklyn ImmunoTherapeutics<\/strong>\n <\/p>\n

Brooklyn is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. The company is also exploring opportunities to advance oncology, blood disorder, and monogenic disease therapies using highly innovative gene editing\/cell therapy technology through the newly acquired license from Factor Bioscience and Novellus Therapeutics.<\/p>\n

Brooklyn\u2019s most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.<\/p>\n

For more information about Brooklyn and its clinical programs, please visit www.BrooklynITx.com<\/a>.<\/p>\n

\n Investor Relations Contact:<\/strong>
\n
CORE IR
516-222-2560
investors@brooklynitx.com<\/a><\/p>\n

\n Media Contact:<\/strong>
\n
CORE IR
Jules Abraham
julesa@coreir.com<\/a>
917-885-7378<\/p>\n<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

BROOKLYN, N.Y., June 08, 2021 (GLOBE NEWSWIRE) — Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing\/cell therapy can have in treating patients with cancer, blood disorders, and monogenic disorders, today announced the appointment of Kevin A. D\u2019Amour, Ph.D. as its Chief Scientific Officer. Dr. D\u2019Amour joins Brooklyn from ViaCyte, Inc., a private, clinical stage company developing stem cell-based therapy for type 1 and insulin-dependent type 2 diabetes, where he most recently served as Chief Scientific Officer. He holds more than 100 U.S. and international patents and has been widely published in nationally and internationally recognized peer review journals. Dr. D\u2019Amour received his Ph.D. in Biology from the University … <\/p>\n

Continue reading “Brooklyn ImmunoTherapeutics Welcomes Dr. Kevin A. D\u2019Amour as Chief Scientific Officer”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-501694","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBrooklyn ImmunoTherapeutics Welcomes Dr. Kevin A. D\u2019Amour as Chief Scientific Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-welcomes-dr-kevin-a-damour-as-chief-scientific-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Brooklyn ImmunoTherapeutics Welcomes Dr. Kevin A. D\u2019Amour as Chief Scientific Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BROOKLYN, N.Y., June 08, 2021 (GLOBE NEWSWIRE) — Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing\/cell therapy can have in treating patients with cancer, blood disorders, and monogenic disorders, today announced the appointment of Kevin A. D\u2019Amour, Ph.D. as its Chief Scientific Officer. Dr. D\u2019Amour joins Brooklyn from ViaCyte, Inc., a private, clinical stage company developing stem cell-based therapy for type 1 and insulin-dependent type 2 diabetes, where he most recently served as Chief Scientific Officer. He holds more than 100 U.S. and international patents and has been widely published in nationally and internationally recognized peer review journals. Dr. D\u2019Amour received his Ph.D. in Biology from the University … Continue reading "Brooklyn ImmunoTherapeutics Welcomes Dr. Kevin A. D\u2019Amour as Chief Scientific Officer"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-welcomes-dr-kevin-a-damour-as-chief-scientific-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-08T11:36:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MDUzNCM0MjMyMTExIzUwMDA4MDY4NQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-welcomes-dr-kevin-a-damour-as-chief-scientific-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-welcomes-dr-kevin-a-damour-as-chief-scientific-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Brooklyn ImmunoTherapeutics Welcomes Dr. Kevin A. D\u2019Amour as Chief Scientific Officer\",\"datePublished\":\"2021-06-08T11:36:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-welcomes-dr-kevin-a-damour-as-chief-scientific-officer\\\/\"},\"wordCount\":443,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-welcomes-dr-kevin-a-damour-as-chief-scientific-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI1MDUzNCM0MjMyMTExIzUwMDA4MDY4NQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-welcomes-dr-kevin-a-damour-as-chief-scientific-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-welcomes-dr-kevin-a-damour-as-chief-scientific-officer\\\/\",\"name\":\"Brooklyn ImmunoTherapeutics Welcomes Dr. Kevin A. D\u2019Amour as Chief Scientific Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-welcomes-dr-kevin-a-damour-as-chief-scientific-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-welcomes-dr-kevin-a-damour-as-chief-scientific-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI1MDUzNCM0MjMyMTExIzUwMDA4MDY4NQ==\",\"datePublished\":\"2021-06-08T11:36:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-welcomes-dr-kevin-a-damour-as-chief-scientific-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-welcomes-dr-kevin-a-damour-as-chief-scientific-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-welcomes-dr-kevin-a-damour-as-chief-scientific-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI1MDUzNCM0MjMyMTExIzUwMDA4MDY4NQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI1MDUzNCM0MjMyMTExIzUwMDA4MDY4NQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-welcomes-dr-kevin-a-damour-as-chief-scientific-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Brooklyn ImmunoTherapeutics Welcomes Dr. Kevin A. D\u2019Amour as Chief Scientific Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Brooklyn ImmunoTherapeutics Welcomes Dr. Kevin A. D\u2019Amour as Chief Scientific Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-welcomes-dr-kevin-a-damour-as-chief-scientific-officer\/","og_locale":"en_US","og_type":"article","og_title":"Brooklyn ImmunoTherapeutics Welcomes Dr. Kevin A. D\u2019Amour as Chief Scientific Officer - Market Newsdesk","og_description":"BROOKLYN, N.Y., June 08, 2021 (GLOBE NEWSWIRE) — Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing\/cell therapy can have in treating patients with cancer, blood disorders, and monogenic disorders, today announced the appointment of Kevin A. D\u2019Amour, Ph.D. as its Chief Scientific Officer. Dr. D\u2019Amour joins Brooklyn from ViaCyte, Inc., a private, clinical stage company developing stem cell-based therapy for type 1 and insulin-dependent type 2 diabetes, where he most recently served as Chief Scientific Officer. He holds more than 100 U.S. and international patents and has been widely published in nationally and internationally recognized peer review journals. Dr. D\u2019Amour received his Ph.D. in Biology from the University … Continue reading \"Brooklyn ImmunoTherapeutics Welcomes Dr. Kevin A. D\u2019Amour as Chief Scientific Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-welcomes-dr-kevin-a-damour-as-chief-scientific-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2021-06-08T11:36:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MDUzNCM0MjMyMTExIzUwMDA4MDY4NQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-welcomes-dr-kevin-a-damour-as-chief-scientific-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-welcomes-dr-kevin-a-damour-as-chief-scientific-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Brooklyn ImmunoTherapeutics Welcomes Dr. Kevin A. D\u2019Amour as Chief Scientific Officer","datePublished":"2021-06-08T11:36:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-welcomes-dr-kevin-a-damour-as-chief-scientific-officer\/"},"wordCount":443,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-welcomes-dr-kevin-a-damour-as-chief-scientific-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MDUzNCM0MjMyMTExIzUwMDA4MDY4NQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-welcomes-dr-kevin-a-damour-as-chief-scientific-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-welcomes-dr-kevin-a-damour-as-chief-scientific-officer\/","name":"Brooklyn ImmunoTherapeutics Welcomes Dr. Kevin A. D\u2019Amour as Chief Scientific Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-welcomes-dr-kevin-a-damour-as-chief-scientific-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-welcomes-dr-kevin-a-damour-as-chief-scientific-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MDUzNCM0MjMyMTExIzUwMDA4MDY4NQ==","datePublished":"2021-06-08T11:36:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-welcomes-dr-kevin-a-damour-as-chief-scientific-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-welcomes-dr-kevin-a-damour-as-chief-scientific-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-welcomes-dr-kevin-a-damour-as-chief-scientific-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MDUzNCM0MjMyMTExIzUwMDA4MDY4NQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MDUzNCM0MjMyMTExIzUwMDA4MDY4NQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-welcomes-dr-kevin-a-damour-as-chief-scientific-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Brooklyn ImmunoTherapeutics Welcomes Dr. Kevin A. D\u2019Amour as Chief Scientific Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/501694","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=501694"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/501694\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=501694"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=501694"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=501694"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}